Daewoong Pharmaceutical Builds Digital Healthcare Alliance Around AI Diagnostics and Patient Monitoring
Daewoong Pharmaceutical is expanding beyond its traditional drug business by building a digital healthcare ecosystem that connects 12 Korean health-tech companies across AI diagnostics, wearable devices, digital therapeutics and patient monitoring.The strategy was put on display at KHF (K-Hospital H
Daewoong Pharmaceutical is creating a digital healthcare alliance that integrates 12 Korean health-tech companies, focusing on AI diagnostics, wearable devices, digital therapeutics, and patient monitoring. This strategy was showcased at KHF (K-Hospital Health Tech Fair) 2026 in Seoul, where Daewoong presented its "DAEWOONG Alliance" platform designed to connect technologies throughout the patient journey, from prevention and prediction to post-treatment monitoring.
The alliance aims to transition Daewoong from a drug developer to a connector of technology companies, medical institutions, and patients.
The alliance is centered around four stages of healthcare: prevention and prediction, early diagnosis, treatment, and post-treatment monitoring and clinical efficiency. During KHF 2026, the alliance featured a 20-booth exhibition area and 34 expert sessions, attracting around 23,000 visitors and 700 attendees. The alliance could play a significant role in the commercialization of digital health technologies, offering benefits to both Daewoong and the participating health-tech companies.
Daewoong's extensive medical network, built over decades, could facilitate the adoption of partner technologies by hospitals and clinics, making the alliance a more significant commercialization platform than simply a portfolio of investments or distribution agreements.
Written by urgent.news from Korea IT Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
